New hope for rare cancers: immunotherapy drug dostarlimab takes on chemo in phase 2 trial
NCT ID NCT06333314
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether the immunotherapy drug dostarlimab can work better than standard chemotherapy as a first treatment for people with rare, advanced cancers that have a specific genetic flaw called dMMR/MSI. The study includes 120 adults with cancers like pancreatic, stomach, or small bowel cancer that cannot be surgically removed. Patients are randomly assigned to receive either dostarlimab or chemotherapy, and those on chemotherapy may switch to dostarlimab if their disease gets worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dostarlimab (an immunotherapy drug that helps the immune system attack cancer cells)
What this could lead to
If it works, this could provide a new first-line treatment option for people with rare cancers that have specific genetic features, potentially delaying disease progression.
What could go wrong
This is a phase 2 trial with only 120 participants, so results are preliminary. The drug may not work better than chemotherapy, and immunotherapy can cause immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU - Henri Mondor
NOT_YET_RECRUITINGCréteil, France
Contact
-
CHU Jean Minjoz
NOT_YET_RECRUITINGBesançon, France
Contact
-
CHU Morvan
NOT_YET_RECRUITINGBrest, France
Contact
-
CHU de Bordeaux - Hôpital Haut -Lèvêque
NOT_YET_RECRUITINGPessac, France
Contact
-
CHU de Poitiers
NOT_YET_RECRUITINGPoitiers, France
Contact
-
CHU de Rouen
NOT_YET_RECRUITINGRouen, France
Contact
-
CHU de Toulouse Hôpital Rangueil
NOT_YET_RECRUITINGToulouse, France
Contact
-
Centre Eugène Marquis
NOT_YET_RECRUITINGRennes, France
Contact
-
Centre François Baclesse
NOT_YET_RECRUITINGCaen, France
Contact
-
Centre Georges François Leclerc
NOT_YET_RECRUITINGDijon, France
Contact
-
Centre Jean Perrin
NOT_YET_RECRUITINGClermont-Ferrand, France
Contact
-
Centre Léon Bérard
RECRUITINGLyon, France
Contact
-
Gustave Roussy Grand Paris
NOT_YET_RECRUITINGVillejuif, France
Contact
-
Hôpital Saint-Antoine
NOT_YET_RECRUITINGParis, Île-de-France Region, France
Contact
-
Hôpital la Timone
NOT_YET_RECRUITINGMarseille, France
Contact
-
Institut Jean Godinot
NOT_YET_RECRUITINGReims, France
Contact
-
Institut Mutualiste Montsouris
NOT_YET_RECRUITINGParis, France
Contact
-
Institut Paoli Calmettes
NOT_YET_RECRUITINGMarseille, France
Contact
-
Institut de Cancérologie de Lorraine
NOT_YET_RECRUITINGNancy, France
Contact
-
Institut de Cancérologie de l'Ouest
NOT_YET_RECRUITINGAngers, France
Contact
-
Institut de Cancérologie de l'Ouest
NOT_YET_RECRUITINGSaint-Herblain, France
Contact
-
Institut du Cancer Avignon-Provence
NOT_YET_RECRUITINGAvignon, France
Contact